Articles On Neuren Pharmaceuticals (ASX:NEU)

Neuren Pharma (ASX:NEU) has popped 20% as the FDA greenlights its upcoming Phase 3 trial in children with Phelan-McDermid syndrome (PMS) – the first ever to be conducted. Listen to the HotCopper podcast for in-depth discussions and insi...

The ASX has been up 1% higher at 7,721 points. Invictus Energy (ASX:IVZ) has been among the most watched on HotCopper forums after the company confirmed Musuma-1 as the first high-impact exploration well to be drilled outside the Mukuyu...

The S&P/ASX 200 Index (ASX: XJO) has followed Wall Street's lead and is pushing higher. At the time of writing, the benchmark index is up 1.1% to 7,728.6 points. Four ASX shares that are rising more than most today are listed below. He...

Neuren Pharmaceuticals Ltd (ASX: NEU) shares are starting the week with an almighty bang. In morning trade, the ASX 200 biotech stock is up a massive 18% to $10.83. Why is this ASX 200 stock jumping? Investors have been bidding the pharmace...

Highlights Major U.S. indexes, including the S&P 500 and Nasdaq, experience significant overnight gains. Australian pharmaceutical stocks fluctuate after recent tariff updates. Investors watch closely for companies that don’t foll...

The US market took off, in a fashion I’ve not seen in my career, after Trump sent this message on his social media platform: “Authorised a 90 day PAUSE, and a substantially lowered Reciprocal Tariff during this period, of 10%, also effectiv...

Highlights: Short interest surged across uranium developers and producers amid sector-wide declines. James Hardie recorded a sharp uptick in short interest after a controversial acquisition. Limited short covering observed,...

Highlights: Neuren Pharmaceuticals reports a price-to-earnings ratio below the broader market. The company's earnings have shown a decline, influencing its valuation. Market expectations indicate continued financial challeng...

Highlights: ASX 200 moves higher with technology and real estate stocks gaining traction. Light & Wonder and Megaport stand out with notable price increases. Some resource stocks experience declines, including Liontown a...

Some investors contend Clinuvel’s mountain of $200 million of cash is excessive and amounts to a ‘lazy’ balance sheet The company argues the cash buffer protects it against unexpected adversities and – in any event – every cent will be nee...

Highlights: ASX200 sees fluctuations as various sectors experience gains and declines. Energy and Consumer Staples lead with positive performances, while Information Technology faces setbacks. Notable stock movements inclu...

The ASX200 closed down 0.38% at 7,969 points. Energy was the best performing sector, up1%, followed by Staples, up 0.4%, and Materials, up 0.33%. Real Estate was the biggest loser, down 2.2%, followed, IT, down 2%, and Discretionary,...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is out of form and dropping into the red. At the time of writing, the benchmark index is down 0.6% to 7,953.4 points. Four ASX shares that are not letting that hold them back are lis...

A cabal of ASX drug developers has defied the US gloom The healthcare jury’s out on new FDA head Dr Marty Makary Emvision’s Emu trial takes flight Amid the downbeat narrative about US healthcare policy and cuts to funding agencies, a ‘Mag...

A couple of ASX 200 biotech stocks are in the spotlight today after releasing big news. However, while one is pushing higher, the other has dropped into the red. Let's see what is happening: Mesoblast Ltd (ASX: MSB) The Mesoblast share pri...

There are several ASX biotech companies developing drugs to treat complex neurological conditions Global neurological disorder drugs market size set to reach US$149.17 billion by 2032 Petra Capital’s Tanushree Jain says neurological disord...

Despite the current political upheaval, the US health sector remains the first port of call for most biotechs FDA approvals have sparked one-day share surges of as much as 500% Several ASX companies await do-or-die FDA approvals Despite r...

The S&P/ASX 200 Index (ASX: XJO) enjoyed a pleasant end to the trading week this Friday, clawing back some of the week's lost ground to finish in the green. By the time the closing bell rang, t...

Profit-making ASX biotechs have been caught up in the market rout During Brain Health Week, let’s not forget about dementia risks Argent looks for Malta site deal While few stocks or sectors have escaped the market correction – or almost...

Many of Australia's top brokers have been busy adjusting their financial models and recommendations again. This has led to the release of a number of broker notes this week. Three ASX shares that brokers have named as buys this week are lis...

Neuren Pharmaceuticals Ltd (ASX: NEU) shares were out of form on Tuesday after getting caught up in the market selloff. The ASX 200 stock ended the day 6% lower at $11.40. This leaves the pharmaceutical company's shares trading within sight...

The Australian share market is a sea of red again on Tuesday. Investors have been hitting the sell button in a panic following a selloff on Wall Street caused by US recession concerns. While the market volatility can be hard to stomach, his...

Healthcare analysts say Neuren shares should be worth more than double what they are Biotech sector retreats in February, despite some record results Dimerix pockets $3.2 million payment from Japanese partner   Some healthcare analysts be...

ASX investors finally caught another break this Thursday, with the S&P/ASX 200 Index (ASX: XJO) rising for only its second session in the past nine trading days. By the time the markets closed...

Highlights: Karoon Energy strengthens its operational framework with an asset acquisition for its Brazil-based project. Qantas announces a dividend reinstatement, reflecting financial recovery in the aviation sector. Fluctuations...

Good afternoon and welcome to the Thursday edition of Market Close, I’m Jonathon Davidson. It was a somewhat happier day as Australian icon Qantas paid its first dividend in years and household name Coles proved to be consistently growing....

The S&P/ASX 200 Index (ASX: XJO) is on course to record a strong gain on Thursday. In afternoon trade, the benchmark index is up 0.4% to 8,272 points. Four ASX shares that are rising more than most today are listed below. Here's why the...

Like London buses, takeovers tend to come in a rush Mayne Pharma had struggled for years, but its performance was improving Takeovers in the ASX biotech sector have been few and far between The ‘London’ Bus theory goes that if one takeove...

The S&P/ASX 200 Index (ASX: XJO) had a wild start to the week's trading this Monday. Overcoming a big opening loss, it finished 0.14% higher by the closing bell, breaking last week's five-day...

The S&P/ASX 200 Index (ASX: XJO) has fought back from a poor start and is down in afternoon trade. At the time of writing, the benchmark index is down slightly to 8,289.8 points. Four ASX shares that are not letting that hold them bac...

The market may be heading lower today but that hasn't stopped two ASX 200 pharmaceutical shares from charging higher. Let's find out what big news out of the United States is giving them a big boost today. Here's what you need to know: Neu...

Neuren Pharmaceuticals (ASX: NEU) has been granted the chance to talk to the U.S. Food and Drug Administration (FDA) about some of the positive indicators that may be expected from its upcoming Phase 3 clinical trial program for a drug to t...

It was a fantastic day for the S&P/ASX 200 Index (ASX: XJO) and many ASX 200 shares this Wednesday, with investors throwing off the negativity that spoiled yesterday's session By the time the...

Highlights: Fisher & Paykel Healthcare (ASX:FPH) faces new tariffs but is adapting with strategic measures. Orthocell (ASX:OCC) is progressing with regulatory approvals in multiple markets. Life-sciences...

Dimerix forecasting second interim analysis of its ACTION3 phase III trial mid CY25 Retinal-diseases-focused biotech Opthea is awaiting two trial results in CY25 Recce set to start trial assessing topical gel to treat diabetic foot infecti...

ASX health stocks up 0.6% over past week, while the broader market rises 1%  EBR Systems is up ~58% in a month, briefly hitting Morgans price target of $1.76 Morgans drops rating of Nanosonics to a hold despite strong H1 FY25 Healthcare a...

The S&P/ASX 200 Index (ASX: XJO) ended its trading week on a low this Friday, banking a loss after a wild trading session. After spending some of the day comfortably in green territory, invest...

Pic via Getty ImagesRadiopharmaceuticals company Telix reports sustained revenue growth in Q4 FY24 ASX health stocks fall about 2.8% over past week Neuren’s partner Acadia submits marketing authorisation application in Europe for trofine...

It was a jubilant Thursday session for the S&P/ASX 200 Index (ASX: XJO) and most ASX shares today, giving investors some much-needed relief. After a shaky week, the ASX 200 wasn't holding back...

Highlights ASX climbs 1.4% after robust jobs data. Commonwealth Bank (CBA) gains 2.7%. Neuren Pharmaceuticals (NEU) sees biggest single-session rise of 9%.   The Australian stock market rallied on Thursday, with the S&P/ASX 2...

The ASX200 closed down 0.22% at 8,213 points. The local bourse gave up early gains and slipped into the red in afternoon trade, and did not return to positive territory. The Discretionary sector was the best performer, up 0.2%, follow...

After a strong start to the morning's trade, things don't look so upbeat for the S&P/ASX 200 Index (ASX: XJO) this afternoon. At the time of writing, the ASX 200 has given up most of its early lead today, and is sitting pretty much flat...

The S&P/ASX 200 Index (ASX: XJO) is running out of steam and fighting hard to stay in positive territory. In afternoon trade, the benchmark index is up slightly to 8,230.9 points. Four ASX shares that are weighing on the market today...

Are you a fan of growth stocks? If you are, then it could be worth looking at the two ASX 200 growth shares listed below. That's because they have been named as buys by brokers and tipped to rise strongly from current levels. Here's what th...

It was another pleasant day for the S&P/ASX 200 Index (ASX: XJO) and Australian investors this Wednesday. After tentatively rising all week, investors stepped on the buying pedal this hump day...

The S&P/ASX 200 Health Care Index fell 1.85% in December but rose 7.51% overall in 2024  Mesoblast surged 52% in December after the US FDA approved its cell therapy Ryoncil for treatment of paediatric GvHD Percheron plunged 91% in Dece...

Do you have $10,000 to invest into ASX 200 shares in January? If you do, then it could be worth considering the two shares in this article. Let's see why they could be great options for investors this month: Neuren Pharmaceuticals Ltd (AS...

Highlights - The ASX 200 index closed 0.92% lower during the final session of 2024.  - Nine out of eleven sectors recorded declines, led by gold and consumer-focused stocks.  - Energy stocks were the top performers as crude prices sup...

Morgans sees opportunities among several ASX healthcare stocks in 2025 Broker looking at stocks with near-term catalysts or sold down with good entry opportunities Morgans’ Christmas stocking has mix of up-and-comers alongside mature names...

Looking for growth stocks to buy in 2025? If you are, then it could be worth looking at the three ASX 200 growth shares listed below. They have been named as buys by brokers and tipped to rise strongly from current levels. Here's what they...